Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Q2 2025 Earnings Presentation
16 slides from Tarsus Pharmaceuticals's earnings presentation, Aug 6, 2025
Slide 1: Second Quarter 2025 Financial Results Conference Call
Second Quarter 2025 Financial Results Conference Call August 6, 2025 Matt, an XDEMVY® Patient
Slide 2: Today's Speakers
Today’s Speakers Bobby Azamian, MD, PhD Aziz Mottiwala Jeff Farrow CEO & Chairman Chief Commercial Officer Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements and the most recent Form 10-Q quarterly filing filed with the SEC include statements regarding the potential commercial success and growth of XDEMVY in Demodex blep
Slide 4: Tarsus: Poised to Potentially Lead the Next Era in Eye Care
Tarsus Poised to Potentially Lead the Next Era in Eye Care XDEMVY: Already one of the Category creating blueprint Differentiated and most successful launches1 expanding pipeline $102.7 A management team with a proven track record of $78.3 execution $66.4 $48.1 Unconventional approach $40.8 to innova
Slide 5: XDEMVY: On Track to be a Potential Blockbuster-Plus Therapeutic
XDEMVY® On Track to be a Potential Blockbuster-Plus Therapeutic XDEMVY Net Sales XDEMVY Bottles ($ in millions) +152% Delivered to Patients YoY growth (in thousands) $102.7 91.0 $78.3 72.0 $66.4 58.5 $48.1 41.4 $40.8 37.0 26.0 $24.7 15.7 $13.1 $1.7 1.7 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25
Slide 6: Making XDEMVY a Household Name
Making XDEMVY a Household Name Direct-To-Consumer Campaign: Meaningfully Growing Prescription Volumes 6 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 7: Differentiated and Advancing Pipeline
Differentiated and Advancing Pipeline Creating First-in-Class Therapeutics for Underserved Diseases Ocular Rosacea Another clear and damaging ocular disease caused by Demodex mites “Having a lotilaner gel for ~15-18M ocular rosacea would be life-changing for patients.” People affected in the U.S.1 -
Slide 8: Tarsus: Poised to Potentially Lead the Next Era in Eye Care
Tarsus Poised to Potentially Lead the Next Era in Eye Care Category creator with a proven blueprint and top-tier talent XDEMVY: One of the most successful launches with blockbuster-plus potential Differentiated and expanding pipeline targeting large, underserved populations Potentially leading the n
Slide 9: XDEMVY: One of the Fastest Rx Eye Drops to Exceed $100M in Quarterly Sales
XDEMVY One of the Fastest Rx Eye Drops to Exceed $100M in Quarterly Sales $120 $102.7M $100 $78.3M +152% Net Sales ($M) $80 $66.4M YoY growth $60 $48.1M +31% $40.8M $40 $24.7M $20 QoQ growth $13.1M $1.7M $0 9 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 10: Direct-To-Consumer Campaign is Driving New Prescriptions
Direct-To-Consumer Campaign is Driving New Prescriptions 3X ~400% >20K Increased unaided Increase in website engagement ECPs prescribing XDEMVY3 consumer awareness1 including high-value actions2 ~91,000 Bottles Delivered to Patients in Q2 2025 1. Since the beginning of the DTC campaign. 2. Percent i
Slide 11: Driving Increased Depth of Utilization
Driving Increased Depth of Utilization 80% of ECPs Prescribing Across All Patient Segments1 Demodex Blepharitis MGD Patients Dry Eye Rx Patients Cataract Patients Contact Lens Patients Patients with DB with DB with DB with DB ~9M ~5,000 90% Patients proactively seeking ECPs prescribing XDEMVY Commer
Slide 12: XDEMVY: Key Growth Drivers to Blockbuster-Plus Potential
XDEMVY Key Growth Drivers to Blockbuster-Plus Potential Exceptional Sales Force Increasing utilization across all patient segments Action-oriented Direct-to-Consumer Campaign Meaningfully contributing to prescriptions Expanding Prescriber Base >20,000 ECPs writing XDEMVY1 High Quality Market Access
Slide 13: Strong Second Quarter Results
Strong Second Quarter Results $102.7M ~91,000 XDEMVY Net Sales XDEMVY Bottles ($ in millions) Delivered to Patients +152% ~45% YoY Net Sales Growth Gross-to-Net Discount 13 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 14: Third Quarter Outlook
Third Quarter Outlook Strong Momentum & Continued Execution Position Us for Expected Growth Prescription Demand Gross-To-Net Discount ~95-100K ~43-45% XDEMVY bottles expected with improvement expected to be dispensed to patients throughout the year 14 | © Tarsus Pharmaceuticals | For Investor Purpos
Slide 15: Pipeline and Global Expansion Progress
Pipeline and Global Expansion Progress Greater U.S. Europe Japan China* TP-04 for ocular rosacea: XDEMVY for DB: TP-03 for DB: TP-03 for DB: Plans to initiate Ph 2 trial in H2 2025 On-track for potential regulatory Anticipate meeting with New Drug Application accepted TP-05 for Lyme approval in 2027
Slide 16: Q&A
Q&A Bobby Azamian, MD, PhD Aziz Mottiwala Jeff Farrow CEO & Chairman Chief Commercial Officer Chief Financial & Strategy Officer 16 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Tarsus Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix